Celyad SA (CYAD) IPO Prices at $68.56/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Celyad raises $100.1 million gross proceeds with NASDAQ IPO
June 18, 2015 7:45 PM EDTMONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--
Regulatory News:
Celyad SA (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris: CYAD), today announced the pricing of its global offering totaling $100.1 million gross proceeds of 1,460,000 new ordinary shares, consisting of 1,168,000 American Depositary Shares (ADSs) at $68.56 per ADS, and 292,000 ordinary shares at a price of EUR 60.25 per share, both before underwriting discounts. These shares were placed in a concurrent public offering in the United States and private placement in Europe (together the global offering). The price per ADS was based on EUR 60.25 per ordinary share at an exchange rate of $ 1.1380 per... More
Celyad Raises $100.1 Million Gross Proceeds With NASDAQ IPO
June 18, 2015 7:10 PM EDTMONT-SAINT-GUIBERT, Belgium, June 18, 2015 (GLOBE NEWSWIRE) -- Celyad SA (formerly known as Cardio3 BioSciences) (Euronext Brussel: CYAD) (Paris: CYAD), today announced the pricing of its global offering totaling $100.1 million gross proceeds of 1,460,000 new ordinary shares, consisting of 1,168,000 American Depositary Shares ("ADSs") at $68.56 per ADS, and 292,000 ordinary shares at a price of EUR 60.25 per share, both before underwriting discounts. These shares were placed in a concurrent public offering in the United States and private placement in Europe (together the "global offering"). The price per ADS was based on EUR 60.25 per... More
